DARPA selects Continuity Pharma to develop continuous manufacturing technology

The company has been selected for a $1.5 million grant

The COVID-19 pandemic has created supply chain gaps in critical drug products, especially those needed for the most critical patients in intensive care units across the country.

DARPA (Defense Advanced Research Project Agency) has selected Continuity Pharma to develop Continuous Manufacturing technology. The company was selected for a $1.5 million grant.

DARPA has established a competitive review process, awarding grant funding to companies presenting Advanced Manufacturing Technologies.

Continuity Pharma’s mission is to apply novel continuous manufacturing capabilities to reshore generic drug products to the US, with specific focus on drugs in short supply.

“We are thrilled to be selected by DARPA to further our development efforts,” said Dr David Thompson, co-founder and Chief Scientific Officer. “We are one step closer to ensuring the availability of essential medicines to patients in need, it is an exciting time for Continuity Pharma.”

Grant specifics include development funding over the next 24 months, with additional funding for commercialisation in the subsequent 12 months. Focus areas include capabilities for multiple API manufacturing in the Integrated Continuous Manufacturing System (ICMS), with demonstrated efficiencies for rapid changeover and manufacturing efficiencies.